Citadel Advisors’s Akari Therapeutics AKTX Stock Holding History

Citadel Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-832	Closed	-$99.1K	–	14433
2024 Q3	$99.1K	Buy	+832	New	+$116K	﹤0.01%	11125
2023 Q1	–	Sell	-19	Closed	-$7.57K	–	14652
2022 Q4	$7.57K	Buy	+19	New	+$7.86K	﹤0.01%	13817
2022 Q3	–	Sell	-19	Closed	-$15K	–	12520
2022 Q2	$15K	Buy	+19	New	+$16.8K	﹤0.01%	12487
2021 Q4	–	Sell	-47	Closed	-$62K	–	13722
2021 Q3	$62K	Sell	47 -18	-28%	-$24.5K	﹤0.01%	13241
2021 Q2	$90K	Buy	65 +30	+86%	+$48K	﹤0.01%	12993
2021 Q1	$73K	Buy	+35	New	+$79.3K	﹤0.01%	12706
2020 Q3	–	Sell	-24	Closed	-$41K	–	10018
2020 Q2	$41K	Buy	+24	New	+$36.6K	﹤0.01%	9385
2015 Q3	–	Sell	-2	Closed	-$9K	–	8836
2015 Q2	$9K	Sell	2 -2	-50%	-$10.2K	﹤0.01%	8428
2015 Q1	$22K	Buy	+4	New	+$100K	﹤0.01%	7839

Other funds holding AKTX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OFW

Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

CCG

Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return

ACM

Accent Capital Management Centerville, Ohio $206M AUM 29.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's AKTX Position: Q4 2024 in Review

Citadel Advisors sold out of Akari Therapeutics (AKTX) in Q4 2024, closing a stake of 832 shares — an estimated $99.1K sold.

Citadel Advisors first reported a position in AKTX in Q1 2015 and held it in 9 quarters. The position peaked at $99.1K in Q3 2024. 11 funds tracked by Wall St. Rank hold AKTX as of Q4 2024.

Citadel Advisors reported no remaining Akari Therapeutics position as of Q4 2024 after selling out during the quarter.
Citadel Advisors sold 832 Akari Therapeutics shares in Q4 2024, an estimated $99.1K.
Citadel Advisors first reported a position in Akari Therapeutics in Q1 2015 and held it in 9 quarters.
Citadel Advisors's Akari Therapeutics position peaked at $99.1K in Q3 2024.
11 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.